Clinical trial
A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer (SHARP-SCLC)
NCT07920549 is registered in ClinicalTrials.gov with London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer (SHARP-SCLC)
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- September 30, 2036
- Enrollment
- 150 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
limited stage small-cell lung cancer
Arms
As registered; 2 arms.
-
Standard Thoracic Radiotherapy
-
Hypofractionated Accelerated Thoracic Radiotherapy
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Progression-free survival
Progression-free survival (PFS) is defined as the time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first. Disease progression will be assessed using RECIST version 1.1 criteria. Participants without documented progression or death will be censored at the date of their last adequate disease assessment.
Lead sponsor's other trials
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, most recent start first.
+702 more trials See the organization page
Similar trials
Same condition (Small Cell Lung Carcinoma) and phase, most recent start first.
+7 more trials See the condition page